Dragan Cicic, MD, MBA
President and CEO
Dragan Cicic is the President and CEO of Actinium Pharmaceuticals, Inc. (API). He joined the company in 2005 and previously held the position of the Medical Director with Actinium Pharmaceuticals, Inc. Dr. Cicic joined API from the position of Project Director of QED Technologies Inc., a life sciences strategic consulting and transactional group focused on emerging biotech, pharmaceuticals and medical devices companies. Dr. Cicic prepared business and strategic plans on behalf of those clients and assisted them in raising funding. He also represented corporate and private investors in identifying acquisition and/or investment targets and negotiating, structuring and consummating deals. Prior to joining QED Technologies, Dr. Cicic was an investment banker with SG Cowen Securities.
Dr. Cicic graduated as a Medical Doctor from the School of Medicine at The Belgrade University, and received his MBA from Wharton School at The University of Pennsylvania. He was also a Nieman Fellow at Harvard University.
Richard Sherman, JD
General Counsel
Richard L. Sherman spent more than a decade (1976-1989) as Deputy General Counsel of SmithKline Beckman Corporation (now GlaxoSmithKline) and was founder and managing officer (1992-2001) of QED Technologies, Inc., a life science business consulting firm. He maintains a consulting practice in the life sciences industry, is a consultant to the Honolulu law firm of Goodsill Anderson Quinn & Stifel and is a principal in a private SBIC Investment fund, CIP Capital, L.P. in Philadelphia, as well as a Venture Partner of SCP Private Equity Partners and SCP/Vitalife II, venture funds located in suburban Philadelphia. Mr. Sherman has served on the Board of Directors of CytoMed, Inc., IBAH, Inc.; Kenna Technologies, Inc., Mera Pharmaceuticals, Inc., Pennsylvania Biotechnology Association, Biophage, Inc., Hawaii Biotech, Inc. and Sparta Pharmaceuticals; as a member of the investment advisory committee of the Ben Franklin Technology Center, and on the Executive Board of the START Technology Partnership, a consortium of Delaware Valley universities, as a Board member of the Sbarro Health Research Organization, the Advisory Board of the University of Hawaii Medical School, the Technology Advisory Committee of Children’s Hospital of Philadelphia, and the Boards of the Hawaii Venture Capital Association and Hawaii Science and Technology Council. He is currently a member of the Board of Directors of Functional Technologies Corp, which is traded on the Toronto Venture Exchange.
Mr. Sherman graduated magna cum laude from the University of Nebraska (1968), where he was elected to Phi Beta Kappa. As a Root-Tilden Scholar at the New York University School of Law, he earned his Juris Doctor in 1971.
Betsy C. King
Regulatory Affairs Director
Betsy C. King is the Quality Assurance and Regulatory Affairs Director with Actinium Pharmaceuticals. Ms. King has more than thirty-five years of senior level experience in quality assurance, quality control and regulatory affairs.Prior to joining API, Ms. King served as VP of Quality Assurance for Mannatech Inc., Director of Quality and Regulatory Affairs for International Isotopes Inc., Department Manager for Quality Assurance at Pacific Northwest National Laboratory, and Manager of Quality and Compliance for DuPont Medical Products. In these positions Ms. King successfully established quality systems compliant with GMP drug, device and dietary supplement requirements. In addition, Ms. King has broad experience with U.S. FDA, EU Commission, Health Canada and Australian TGA submission requirements for drugs, devices and dietary supplements.
Ms. King’s technical experience includes hands-on research and testing experience in pharmaceuticals and radiopharmaceuticals. Her experience base includes FDA audit training, implementation of cGMP requirements, and preparation of NDA, DMF, IND and 510K submissions. Ms. King earned her undergraduate degree in Chemistry from the University of New York at Buffalo.
Gaylord King
Manufacturing Director
Gaylord King the Manufacturing Director with Actinium Pharmaceuticlas. Mr. King has over 35 years of experience and a technical base that includes basic research, development, production under cGMP requirements, submissions for FDA approval, distribution and administration of products to patients. In addition, he has directed and developed environmental analytical testing laboratories that have received awards for efficiency. Mr. King’s experience includes both the private sector and government organizations. He has worked with pharmaceuticals,radiopharmaceuticals and medical devices.
Prior to assuming his position with Actinium Pharmaceuticals, Mr. King was a consultant and before that Vice–President of International Isotopes, Inc. with responsibilities for strategic planning, start-up operations, new product development, staffing, designing facilities and operations. Prior to joining International Isotopes, Mr. King directed environmental testing facilities for the Department of Energy where he had operational, strategic planning, regulatory compliance and contract negotiation responsibilities. Mr. King has also directed operations for radiopharmaceutical manufacturing for DuPont and Medi+Physics. Mr. King is a frequent speaker at industry meetings and he has published numerous technical publications. He earned his undergraduate degree in Chemistry from the University of Tennessee and a graduate degree in Management from the University of Vermont.